1 |
Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study [J]. Stroke. 2007, 38(6): 1881-1885.
|
2 |
Weiwei C, Runlin G, Lisheng L, et al. Outline of the report on cardiovascular diseases in China, 2014 [J]. Eur Heart J Suppl. 2016, 18(Suppl F): F2-F11.
|
3 |
Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project) [J]. Lancet. 2017, 390(10112): 2549-2558.
|
4 |
Tang X, Laskowitz DT, He L, et al. Neighborhood socioeconomic status and the prevalence of stroke and coronary heart disease in rural China: a population-based study [J]. Int J Stroke. 2015, 10(3): 388-395.
|
5 |
Reddy KS. Cardiovascular disease in non-Western countries [J]. N Engl J Med. 2004, 350(24): 2438-2440.
|
6 |
Willett WC, Stampfer MJ. Rebuilding the food pyramid [J]. Sci Am. 2003, 288(1): 64-71.
|
7 |
Renaud S, de Lorgeril M, Delaye J, et al. Cretan Mediterranean diet for prevention of coronary heart disease [J]. Am J Clin Nutr. 1995, 61(6 Suppl): 1360S-1367S.
|
8 |
Estruch R, Ros E, Salas-Salvado J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts [J]. N Engl J Med. 2018, 378(25): e34.
|
9 |
Willett WC, Stampfer MJ. Rebuild the food pyramid [J]. Scientific American 2003; 1: 64-71. Scientific American. 2003(January):64-71.
|
10 |
Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet [J]. N Engl J Med. 2008, 359(3): 229-241.
|
11 |
Bogiatzi C, Gloor G, Allen-Vercoe E, et al. Metabolic products of the intestinal microbiome and extremes of atherosclerosis [J]. Atherosclerosis. 2018, 273: 91-97.
|
12 |
Pignanelli M, Bogiatzi C, Gloor G, et al. Moderate Renal Impairment and Toxic Metabolites Produced by the Intestinal Microbiome: Dietary Implications [J]. J Ren Nutr. 2019;, 29(1): 55-64.
|
13 |
Spence JD, Urquhart BL, Bang H. Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine [J]. Nephrol Dial Transplant. 2016, 31(6): 937-944.
|
14 |
Bonita R, Duncan J, Truelsen R, Jackson RT, Beaglehole R. Passive smoking as well as active smoking increases the risk of acute stroke [J]. Tobacco Control. 1999, 8: 156-160.
|
15 |
Epstein KA, Viscoli CM, Spence JD, et al. Smoking cessation and outcome after ischemic stroke or TIA [J]. Neurology. 2017, 89(16): 1723-1729.
|
16 |
Reid RD, Mullen KA, Slovinec D'Angelo ME, et al. Smoking cessation for hospitalized smokers: an evaluation of the "Ottawa Model" [J]. Nicotine Tob Res. 2010, 12(1): 11-18.
|
17 |
Du S, Batis C, Wang H, Zhang B, Zhang J, Popkin BM. Understanding the patterns and trends of sodium intake, potassium intake, and sodium to potassium ratio and their effect on hypertension in China [J]. Am J Clin Nutr. 2014, 99(2): 334-343.
|
18 |
Juraschek SP, Miller ER, 3rd, Weaver CM, Appel LJ. Effects of Sodium Reduction and the DASH Diet in Relation to Baseline Blood Pressure [J]. J Am Coll Cardiol. 2017.
|
19 |
Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial [J]. JAMA. 2015;313(13): 1325-1335.
|
20 |
Huang X, Li Y, Li P, et al. Association between percent decline in serum total homocysteine and risk of first stroke [J]. Neurology. 2017, 89(20): 2101-2107.
|
21 |
Qin X, Li J, Spence JD, et al. Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients [J]. Stroke. 2016, 47(11): 2805-2812.
|
22 |
Kong X, Huang X, Zhao M, et al. Platelet Count Affects Efficacy of Folic Acid in Preventing First Stroke [J]. J Am Coll Cardiol. 2018, 71(19): 2136-2146.
|
23 |
Wang CY, Chen ZW, Zhang T, et al. Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients [J]. Eur J Intern Med. 2014, 25(6): 538-544.
|
24 |
Spence JD, Barnett PA, Hegele RA, Marian AJ, Freeman D, Malinow MR. Plasma Homocyst(e)ine, but not MTHFR genotype, is associated with variation in carotid plaque area [J]. Stroke. 1999, 30: 969-973.
|
25 |
Qin X, Spence JD, Li J, et al. Interaction of serum vitamin B12 and folate with MTHFR genotypes on risk of ischemic stroke [J]. Neurology. 2019; In Press.
|
26 |
Li Y, Spence JD, Wang X, Huo Y, Xu X, Qin X. Effect of Vitamin B12 Levels on the Association Between Folic Acid Treatment and CKD Progression: A Post Hoc Analysis of a Folic Acid Interventional Trial [J]. Am J Kidney Dis. 2019.
|
27 |
Spence JD, Yi Q, Hankey GJ. B vitamins in stroke prevention: time to reconsider [J]. Lancet Neurol. 2017, 16(9): 750-760.
|
28 |
Spence JD. The need for clinical judgement in the application of evidence-based medicine [J]. BMJ Evid Based Med. 2019.
|
29 |
Spence JD. Harm With High Levels of Serum B12 in Elderly Persons [J]. J Gerontol A Biol Sci Med Sci. 2019, 74(1): 137.
|
30 |
Soros P, Whitehead S, Spence JD, Hachinski V. Antihypertensive treatment can prevent stroke and cognitive decline [J]. Nat Rev Neurol. 2013, 9(3): 174-178.
|
31 |
Spence JD. Antihypertensive drugs and prevention of atherosclerotic stroke [J]. Stroke. 1986, 17: 808-810.
|
32 |
Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators [J]. N Engl J Med. 1998, 339(20): 1415-1425.
|
33 |
Akintunde A, Nondi J, Gogo K, et al. Physiological Phenotyping for Personalized Therapy of Uncontrolled Hypertension in Africa [J]. Am J Hypertens. 2017, 30(9): 923-930.
|
34 |
Spence JD, Rayner BL. Hypertension in Blacks: Individualized Therapy Based on Renin/Aldosterone Phenotyping [J]. Hypertension. 2018, 72(2): 263-269.
|
35 |
Huang X, Li J, Liu L, et al. Interpreting stimulated plasma renin and aldosterone to select physiologically individualized therapy for resistant hypertension: importance of the class of stimulating drugs [J]. Hypertens Res. 2019, 42(12): 1971-1978.
|
36 |
Spence JD. Systolic blood pressure targets, diastolic J curve and cuff artefact in blood pressure measurement: a note of caution [J]. Eur J Neurol. 2017, 24(11): 1323-1325.
|
37 |
McEvoy JW, Chen Y, Rawlings A, et al. Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control [J]. J Am Coll Cardiol. 2016, 68(16): 1713-1722.
|
38 |
Park JH, Ovbiagele B. Post-stroke diastolic blood pressure and risk of recurrent vascular events [J]. Eur J Neurol. 2017, 24(11): 1416-1423.
|
39 |
Blanco PJ, Muller LO, Spence JD. Blood pressure gradients in cerebral arteries: a clue to pathogenesis of cerebral small vessel disease [J]. Stroke Vasc Neurol. 2017, 2(3): 108-117.
|
40 |
Spence JD, Sibbald WJ, Cape RD. Pseudohypertension in the elderly [J]. Clin Sci Mol Med. 1978, 55(Suppl. 4): 399s-402s.
|
41 |
Finnegan TP, Spence JD, Wong DG, Wells GA. Blood pressure measurement in the elderly: correlation of arterial stiffness with difference between intra-arterial and cuff pressures [J]. J Hypertens. 1985, 3(3): 231-235.
|
42 |
Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention [J]. Lancet Neurol. 2009, 8(5): 453-463.
|
43 |
Spence JD. Statins do not cause intracerebral hemorrhage [J]. Neurology. 2012, 79(11): 1076-1077.
|
44 |
Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis [J]. Circulation. 2011, 124(20): 2233-2242.
|
45 |
Judge C, Ruttledge S, Costello M, et al. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage-A Meta-Analysis [J]. J Stroke Cerebrovasc Dis. 2019, 28(6): 1703-1709.
|
46 |
Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy [J]. Lancet. 2016, 388(10059): 2532-2561.
|
47 |
Spence JD, Dresser GK. Overcoming Challenges With Statin Therapy [J]. J Am Heart Assoc. 2016, 5(1): 1-13.
|
48 |
Bohula EA, Wiviott SD, Giugliano RP, et al. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [J]. Circulation. 2017, 136(25): 2440-2450.
|
49 |
Bach RG, Cannon CP, Giugliano RP, et al. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial [J]. JAMA Cardiol. 2019.
|
50 |
Mortensen MB, Falk E. Primary Prevention With Statins in the Elderly [J]. J Am Coll Cardiol. 2018, 71(1): 85-94.
|
51 |
Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial [J]. Circulation. 2019, 140(12): 992-1003.
|
52 |
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) [J]. European Heart Journal. 2019.
|
53 |
Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin [J]. Circulation. 2013, 127(3): 377-385.
|
54 |
Wang Y, Zhao X, Lin J, et al. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack [J]. JAMA. 2016, 316(1): 70-78.
|
55 |
Deykin D. Thrombogenesis [J]. N Engl J Med. 1967;276(11): 622-628.
|
56 |
Caplan LR, Fisher M. The endothelium, platelets, and brain ischemia [J]. Rev Neurol Dis. 2007, 4(3): 113-121.
|
57 |
Spence JD. Anticoagulation in patients with Embolic Stroke of Unknown Source [J]. Int J Stroke. 2019, 14(4): 334-336.
|
58 |
Gladstone DJ, Kapral MK, Fang J, Laupacis A, Tu JV. Management and outcomes of transient ischemic attacks in Ontario [J]. CMAJ. 2004, 170(7): 1099-1104.
|
59 |
Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke [J]. N Engl J Med. 2014;370(26): 2467-2477.
|
60 |
Spence JD. Cardioembolic stroke: everything has changed [J]. Stroke Vasc Neurol. 2018, 3(2): 76-83.
|
61 |
Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence [J]. Europace. 2015, 17(4): 514-523.
|
62 |
Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) [J]. J Am Coll Cardiol. 2014, 63(4): 321-328.
|
63 |
Hutchinson EC, Acheson EJ. Strokes: natural history, pathology and surgical treatment [M]. In. Vol 4. London: W.B. Saunders; 1975.
|
64 |
Ozdemir AO, Tamayo A, Munoz C, Dias B, Spence JD. Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism [J]. J Neurol Sci. 2008, 275(1-2): 121-127.
|
65 |
Kent DM, Thaler DE. Is patent foramen ovale a modifiable risk factor for stroke recurrence? [J] Stroke. 2010, 41(10 Suppl): S26-S30.
|
66 |
Kasner SE, Swaminathan B, Lavados P, et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial [J]. Lancet Neurol. 2018, 17(12): 1053-1060.
|
67 |
Tobe J, Bogiatzi C, Munoz C, Tamayo A, Spence JD. Transcranial Doppler is Complementary to Echocardiography for Detection and Risk Stratification of Patent Foramen Ovale [J]. Can J Cardiol. 2016, 32(8): 986 e989-986 e916.
|
68 |
Brott TG, Calvet D, Howard G, et al. Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data [J]. Lancet Neurol. 2019, 18(4): 348-356.
|
69 |
Howard G, Roubin GS, Jansen O, et al. Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials [J]. Lancet. 2016, 387(10025): 1305-1311.
|
70 |
Spence JD. Periprocedural events dominate outcomes of carotid stenting and endarterectomy [J]. Lancet Neurol. 2019, 18(4): 321-322.
|
71 |
Spence JD, Hackam DG. Treating Arteries Instead of Risk Factors. A Paradigm Change in Management of Atherosclerosis [J]. Stroke. 2010, 41(6): 1193-1199.
|
72 |
Spence JD, Coates V, Li H, et al. Effects of Intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis [J]. Arch Neurol. 2010, 67(2): 180-186.
|
73 |
Paraskevas KI, Veith FJ, Spence JD. How to identify which patients with asymptomatic carotid stenosis could benefit from endarterectomy or stenting [J]. Stroke Vasc Neurol. 2018, 3(2): 92-100.
|